Skip to content

Ionis Pharmaceuticals IONS Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent

Debt Securities Available For Sale Accumulated Gross Unrealized Gain Before Tax Noncurrent at other companies

BK
BKBK
$232M-13.4%
Duke Energy logo
Duke EnergyDUK
$6.29B+10.7%
Bank of America logo
Bank of AmericaBAC
$598M+5.8%
IES
IES Holdings, Inc.IESC
$0+100%
Two Harbors Investment Corporation logo
Two Harbors Investment CorporationTWO
Popular logo
PopularBPOP

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept ions:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized gain before tax noncurrent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized gain before tax noncurrent?
Ionis Pharmaceuticals (IONS) reported debt securities available for sale accumulated gross unrealized gain before tax noncurrent of $339K in Q1 2026.
How has Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized gain before tax noncurrent changed year-over-year?
Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized gain before tax noncurrent decreased by 79.4% year-over-year, from $1.65M to $339K.
What is the long-term trend for Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized gain before tax noncurrent?
Over 4 years (2021 to 2025), Ionis Pharmaceuticals's debt securities available for sale accumulated gross unrealized gain before tax noncurrent has grown at a 48.4% compound annual growth rate (CAGR), from $471K to $2.29M.
What does debt securities available for sale accumulated gross unrealized gain before tax noncurrent mean?
The total unrealized profit on non-current debt investments based on current market prices.
How do you interpret debt securities available for sale accumulated gross unrealized gain before tax noncurrent?
An increase suggests that the company's long-term debt holdings are performing well in the current market environment.
How does debt securities available for sale accumulated gross unrealized gain before tax noncurrent compare across companies?
Standard metric for assessing long-term investment performance in corporate balance sheets.